PRESS RELEASE May 23 , 202 2 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced that the results from the randomized controlled clinical trial of Tesomet for weigh t loss in patients with hypothalamic obesity has been published in the

PRESS RELEASE May 20 , 202 2 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced that the Mexican regulatory authority Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) has published on Twitter that its technical

PRESS RELEASE April 30 , 202 2 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced that the English version of the Annual Report for 202 1  is now available on the company’s website,   www.saniona.com .

PRESS RELEASE April 2 7 , 202 2 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced that the Board of Directors of Saniona AB has resolved to change the date of the Annual Report for 2021 from April 29, 202 2 to April 30, 202 2 .

PRESS RELEASE April 2 5 , 202 2 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to the annual shareholders’

PRESS RELEASE April 25 , 202 2 Jørgen Drejer, co-founder and board member, appointed interim Chairman of the Board of Directors ; Thomas Feldthus, co-founder, appointed as CEO ; Anita Milland appointed as CFO The c ompany will pursue partnerships for its late r -stage clinical programs, Tesomet and

PRESS RELEASE March 29 , 202 2 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced a strategic program reprioritization and restructuring intended to immediately and substantially reduce operating expenses and maximize the utility of current

PRESS RELEASE March 2 4 , 202 2 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has initiated the positron emission tomography (PET) stage of its Phase 1 clinical trial of SAN711 . SAN711 is a potential first-in-class GABA-A α3 ion

PRESS RELEASE March 21 , 202 2 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it s ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the next stage . “After successful completion of target

PRESS RELEASE March 1 , 202 2 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced that it will present at multiple upcoming investor conferences. Details are as follows: Redeye Investor Forum – Göteborg, Sweden Date/Time: 10 March 2022, 1:00